<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Relapsing ocular involvement is one of the major manifestations in Adamantiades-<z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease (ABD) </plain></SENT>
<SENT sid="1" pm="."><plain>Combining systemic <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> with <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> is currently the treatment of choice </plain></SENT>
<SENT sid="2" pm="."><plain>Interferon-alpha (IFN-alpha) has proven to be effective in mucocutaneous ABD and has been reported to improve ocular lesions </plain></SENT>
<SENT sid="3" pm="."><plain>We examined the longterm effects of IFN-alpha-2a in a case series of 45 patients with ocular involvement </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Since 1988, 45 patients (79 eyes of 90 eyes) with ocular involvement in ABD have been treated with IFN-alpha (3 x 6-9 Mio IU per wk) </plain></SENT>
<SENT sid="5" pm="."><plain>In the initial <z:hpo ids='HP_0011009'>acute</z:hpo> phase of the disease, patients additionally received short-term <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> (oral <z:chebi fb="2" ids="8378">prednisolone</z:chebi> 100 mg/day), tapered to a maintenance dose of 10 mg/day within 2 weeks </plain></SENT>
<SENT sid="6" pm="."><plain>IFN-alpha-2a was administered as longterm therapy with a mean duration of 30 months (range 1.1-101 mo) </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: IFN-alpha-2a/prednisolone treatment was effective against <z:hpo ids='HP_0002633'>vasculitis</z:hpo>, optic nerve <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e>, and <z:hpo ids='HP_0001101'>iritis</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Sixty-four eyes had no recurrence under therapy </plain></SENT>
<SENT sid="9" pm="."><plain>To date, recurrences have been seen in 26 eyes under IFN-alpha treatment </plain></SENT>
<SENT sid="10" pm="."><plain>Flu-like symptoms were recorded in nearly <z:hpo ids='HP_0000001'>all</z:hpo> patients (n = 43) </plain></SENT>
<SENT sid="11" pm="."><plain>Further side effects were dose-dependent reversible <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (n = 1), <z:hpo ids='HP_0000709'>psychosis</z:hpo> (n = 3), <z:hpo ids='HP_0000716'>depression</z:hpo> (n = 13), <z:hpo ids='HP_0100646'>thyroiditis</z:hpo> (n = 1), and reversible diffuse <z:hpo ids='HP_0001596'>alopecia</z:hpo> (n = 7) </plain></SENT>
<SENT sid="12" pm="."><plain>In our series, 92% of <z:hpo ids='HP_0000001'>all</z:hpo> eyes showed stable or improved visual acuity in longterm followup </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: Longterm remission of <z:hpo ids='HP_0100533'>ocular inflammation</z:hpo> can be achieved with the combination of IFN-alpha and low-dose <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> </plain></SENT>
</text></document>